This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


China approves first domestic mRNA vaccine for COVID-19

Credit: Pixabay/CC0 Public Domain

China has approved its first locally developed messenger RNA (mRNA) vaccine against COVID-19, its manufacturer said Wednesday, months after the relaxation of strict COVID-zero regulations sparked a surge in cases.

The , developed by CSPC Pharmaceutical Group Ltd, has been approved for "emergency use" by Beijing's health regulator, the company said in a statement.

It showed high efficacy in a trial in which it was used as a for people who have been given other types of vaccines, the company added, without offering further details.

mRNA vaccines are considered among the most effective in reducing severe infections and deaths.

While traditional vaccines use a weakened or inactivated germ to prepare the body for a future attack from the real virus, mRNA deploys snippets of genetic material that carry instructions showing the body's cells how to produce a protein—in this case, the spike protein on the coronavirus that causes COVID.

The body's immune system then triggers antibodies to fight off that spike protein, making it ready for when the real coronavirus comes knocking.

Beijing has refused to greenlight mRNA-based vaccines from foreign firms Pfizer-BioNTech and Moderna for public use.

Its vaccination shortfall was widely believed to have led to more severe infections and deaths after lockdowns and mandatory quarantine rules were suddenly dropped in December.

Other Chinese drugmakers including CanSino have previously said they were developing mRNA-based shots to help the country bridge its immunization gap.

© 2023 AFP

Citation: China approves first domestic mRNA vaccine for COVID-19 (2023, March 22) retrieved 29 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

How the new bivalent COVID vaccines work


Feedback to editors